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Accepted 12 January 2012A 34-year-old primigravida was referred to our tertiary
hospital for further management, because of intrauterine fetal
demise and suspected placenta previa accreta, with focal ute-
roplacental hypervascularization despite three doses of meth-
otrexate (MTX) treatment at 24 weeks of gestation. Serum
b-hCG level decreased from 9000 IU/mL to 3000 IU/mL after
the 2nd MTX treatment. The patient had a history of endo-
metriosis and adenomyosis, for which she underwent a lapa-
roscopic surgery and conceived naturally soon after the
procedure. Genetic amniocentesis was performed at 16 weeks
of gestation, because of advanced maternal age, and revealed
a normal 46,XX karyotype.
A sagittal transabdominal ultrasound (US) image shows
a demised fetus and bulky placenta, with multicystic sono-
lucent spaces in the lower half of enlarged placenta paren-
chyma (Fig. 1). A sagittal transabdominal power Doppler US
image shows hypervascularity, with low resistance turbulent
flow surrounding the echogenic uterine lesion (Fig. 2). T2
weighted magnetic resonance imaging (MRI) (Fig. 3) showed
accumulated flow voids just under the central part of the
placenta. The myometrium beneath the abnormal retro-
placental vascular area showed a well defined area with high
to intermediate heterogeneous signal intensity on T2-
weighted MRI.
Prophylactic transcatheter arterial embolization (TAE) of
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through fundal hysterotomy. Manual removal of the placenta
was uneventful. However, a raised nodular mass measuring
3 cm in length at the posterior wall of the uterus was identi-
fied. The resected specimen was sent for histopathology
examination. The nodular mass was composed of prolifera-
tions of medium to large sized mononuclear and multinucle-
ated intermediate trophoblasts and cytotrophoblasts, with cells
of lesion permeating throughout the myometrium and intra-
vascular spread (Fig. 5). There was an absence of mitotic
figures and a low Ki-67 labeling index (<5%), thus exagger-
ated placenta site (EPS) was diagnosed. Postoperatively, serial
US showed unremarkable finding at 7 months follow up
period.
EPS and placenta site trophoblastic tumor (PSTT) origi-
nated from implantation site intermediate trophoblasts (IT).
EPS differs from PSTT, in that it has no confluent growth, no
mitosis and is mixed with deciduas and villous [1]. The serum
b-hCG level in PSTT or EPS is not correlated with tumor
burden or malignant behavior [2]. A decreased Ki-67 labeling
index reflects the non-neoplastic feature of IT. The Ki-67
index in IT of the EPS site was near zero, but in the molar
implantation sites of molar pregnancy, the Ki-67 index was
5.2%  4.0%. In contrast, the Ki-67 index in IT of the
PSTT was 14%  6.9% and in the choriocarcinoma was
69%  20% [3].
It often accompanies proliferation of IT in placenta accreta
[4]. Our case is diagnosed as EPS without evidence of placenta
accreta according to the absence of infiltrating chorionic villi
destruction in the myometrium and we easily separated the
placenta during surgery.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) sagittal transabdominal ultrasound (US) image shows a demised fetus and bulky placenta, with multicystic sonolucent spaces in the lower half of the
enlarged placenta parenchyma; and (B) note the “honeycomb appearance” of cystic molar changes (arrows) were clearly seen in the lower half of placenta (arrows)
adjacent to bladder.
Fig. 2. (A) Sagittal transabdominal power Doppler US image shows hypervascularity with (B) low resistance turbulent flow surrounding the echogenic uterine
lesion.
Fig. 3. Sagittal T2-weighted MRI image shows the posterior uterine wall,
a well defined heterogeneous high to intermediate signal intensity mass
(arrow). Flow void area located between placenta and the uterine mass, with
continuous hypointense inner layer of the myometrium (arrowheads).
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showed ill-defined margins of mass lesions from the
surrounding myometrium [5e7]. Intraplacental multiple irreg-
ular lacunae with a “moth-eaten” appearance and a low resis-
tance turbulent flow, is a characteristic US sign of placenta
accreta/increta/percreta [8,9], but this sonographic sign is not
present in the EPS or PSTT. In addition, myometrial thickness is
<1 mm, or loss of the visualization of the myometrium in
placenta accreta/increta/percreta. However, in EPS and PSTT,
lesions may present as thickenedmyometrium by gray-scale US
examination [5e7]. The MRI image of the EPS showed
a continuous inner layer of myometrium over the hyper-
vascularized area, which would loss in placenta accreta (Fig. 3).
A PSTT appears, sonographically, as small heterogeneous
echogenic uterine lesions surrounded by numerous intra-
myometrial vascular signals, with fluid-filled cysts represent-
ing hemorrhagic areas [10]. It can also appear on a US scan as
a solid tumor invading the myometrial wall [9]. Both PSTT
and EPS are isointense on the T1-weighted image. On the T2-
weighted image, the heterogeneity of both cases is much
different. In EPS cases, the mass is heterogeneous, with high
Fig. 4. Pelvic arteriography shows dilatation and tortuosity of the bilateral uterine arteries and prominent stains over the lower segment of uterus: (A) posterior to
anterior view (PA) view; and (B) left lateral view.
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void area within the mass, except the high to intermediate
signal intensity of the solid part [5,6].
A partial hydatidiform mole involves the combination of
a fetus with localized placental molar degeneration. Classi-
cally, a partial mole presents on US examination as an
enlarged placenta containing multicystic avascular sonolucent
spaces with a “Swiss cheese appearance”, with normal or
high uterine arterial resistance to flow [10]. A pregnancy with
hydropic changed placenta and a demised fetus may resemble
a partial molar pregnancy, and the low HCG level may
exclude the diagnosis. We cannot differentiate our case fromFig. 5. Proliferation of medium to large-sized mononuclear and multinucleated
cytotrophoblasts and intermediate trophoblasts is noted in the whole layer of
the myometrium. (hematoxylin-eosin stain, 100).a partial molar pregnancy or coexistent mole and fetus,
sonographically.
Our case demonstrated characteristic sonographic features
of EPS during pregnancy, and added an imaging differential
diagnosis to partial molar pregnancy, placenta accreta and
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